NR1H4 and metabolic dysfunction-associated steatotic liver disease: Activation of FXR is a promising therapeutic approach for T2DM and non-alcoholic fatty liver disease (NAFLD) [31], indicating that the gut–liver axis functions as a new perspective for the management of T2DM.